Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1348 • 2019 ACR/ARP Annual Meeting
Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Louis Bessette¹, Maxime Dougados ², Eduardo Mysler ³, Mark Genovese ⁴, Cassandra Kinch ⁵, Kenneth Kwok ⁶, Tatjana Lukic ⁶, Tanya Girard ⁵, Pierre-Alexandre Landry ⁵ and Ronald van Vollenhoven ⁷, ¹Laval University, Quebec City, QC, Canada, ²Cochin Hospital, Paris, France, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Stanford University, Stanford, CA, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. In clinical trials, standard criteria for measuring treatment efficacy in patients (pts) with…
Abstract Number: 1378 • 2019 ACR/ARP Annual Meeting
High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
Vibeke Strand¹, Jerome Msihid ², Toshio Kimura ³, Anita Boyapati ³, Gregory St John ⁴ and Wenhui Wei ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Sanofi, Chilly-Mazarin, France, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA) and is elevated in serum and synovial fluid of RA patients. However,…
Abstract Number: 1412 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study
Stanley Cohen¹, Janet Pope ², Boulos Haraoui ³, Eduardo Mysler ⁴, Annette Diehl ⁵, Tatjana Lukic ⁶, Shixue Liu ⁷, Lori Stockert ⁵, Sujatha Menon ⁸ and Edward Keystone ⁹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Western University, London, ON, Canada, ³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁴Organización Médica de Investigación, Buenos Aires, Argentina, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Shanghai, China (People's Republic), ⁸Pfizer Inc, Groton, CT, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The tofacitinib modified-release (MR) 11 mg once daily (QD) formulation was first…
Abstract Number: 1765 • 2019 ACR/ARP Annual Meeting
Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis
Malin Erlandsson ¹, Karin Andersson ¹, Nisha Nair ², Anastasius Damdimopoulos ³, Sofia Silfverswärd ¹, Rille Pullerits ¹, Anne Barton ² and Maria Bokarewa¹, ¹Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ³Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden, Stockholm, Sweden
Background/Purpose: It is known that rheumatoid arthritis (RA) should be treated early and a delay in treatment increases the rate of treatment non-response, joint damage,…
Abstract Number: 1893 • 2019 ACR/ARP Annual Meeting
Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA
Background/Purpose: Chronic inflammation yields higher risk of cardiovascular events (CVE) in patients with rheumatoid arthritis (RA). We recently reported that occult atherosclerosis burden on coronary…
Abstract Number: 2014 • 2019 ACR/ARP Annual Meeting
Loss-of-function of the DNA Repair Nuclease MRE11A Induces Mitochondrial Failure and Tissue Inflammation in Rheumatoid Arthritis
Yinyin Li ¹, Yi Shen ¹, Ke Jin ¹, Zhenke Wen ¹, Wenqiang Cao ¹, Bowen Wu ¹, Ru Wen ¹, Lu Tian ¹, Gerald Berry ¹, Jorg Goronzy ¹ and Cornelia Weyand¹, ¹Stanford University, Stanford, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) accumulate tissue-invasive, pro-inflammatory CD4+ T cells. Such T cells are metabolically reprogrammed, favoring cytokine production, lipogenesis and membrane formation…
Abstract Number: 2236 • 2019 ACR/ARP Annual Meeting
Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations
Jasmin Ma¹, Jon Collins ², Eileen Davidson ², Kelly English ³, Alison Hoens ⁴, Karen Tsui ⁵, Shanon McQuitty ², Louella Sequeira ³ and Linda Li ⁴, ¹Arthritis Research Canada/University of British Columbia, Vancouver, Canada, ²Arthritis Research Canada, Richmond, Canada, ³Arthritis Research Canada, Richmond, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Patient Advisory Board, Toronto, ON, Canada
Background/Purpose: Strength training (ST) rates in people with rheumatoid arthritis (RA) are remarkably low (1-14%), reducing the potential health benefits of ST for this population…
Abstract Number: 2307 • 2019 ACR/ARP Annual Meeting
Intermetatarsal Bursitis Is Prevalent in Patients with Established Rheumatoid Arthritis and Is Associated with Anti-CCP and RF
Hilde Hammer¹, Tore Kvien ² and Lene Terslev ³, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark
Background/Purpose: Ultrasound is sensitive for detection of inflammatory changes in patients with rheumatoid arthritis (RA). Intermetatarsal bursitis (IMB) may be detected by use of longitudinal…
Abstract Number: 2327 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies
Leticia Ferri¹, Grace Crocket ², Yuting Kuang ³, Boris Breznen ⁴ and Mir Sohail Fazeli ⁴, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Bristol-Myers Squibb; Rutgers University, New York City, NY, ³Doctor Evidence, Doctor Evidence, CA, ⁴Doctor Evidence, Santa Monica, CA
Background/Purpose: Shorter life expectancy in RA patients has in part been associated with an increased incidence of cardiovascular disease (CVD). This literature review summarizes the…
Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Karina Bonfiglioli¹, Márcio Sawamura ², Renato Nakagawa ³, Fábio Arimura ³, Diana Rangel ³, Cleonice Bueno ⁴, Ana Cristina de Medeiros Ribeiro ¹, Carlos Carvalho ³, Eloisa Bonfa ⁵, Ronaldo Kairalla ³ and Leticia Kawano-Dourado ⁶, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Division of Radiology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Br, Sao Paulo, Sao Paulo, Brazil, ³Pulmonary Division, Heart Institute (InCor)- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁶University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…
Abstract Number: 2373 • 2019 ACR/ARP Annual Meeting
Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
Sofia Pedro¹, Alyssa Dominique ², Rebecca Schumacher ¹, Yomei Shaw ¹, Kristin Wipfler ¹, Teresa Simon ³ and Kaleb Michaud ⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb*, Princeton, NJ, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: RA causes significant morbidity and mortality. Over the last two decades, several new medications and strategies for treating RA earlier and more aggressively have…
Abstract Number: 2402 • 2019 ACR/ARP Annual Meeting
Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?
Martin Schaefer¹, Jörn Kekow ², Karin Rockwitz ³, Anke Liebhaber ⁴, Angela Zink ⁵ and Anja Strangfeld ⁶, ¹German Rheumatism Research Center, Berlin, Germany, ²Otto von Guericke University Magdeburg and Helios Clinic Vogelsang-Gommern, Vogelsang-Gommern, Germany, ³Rheumatologist, Goslar, Germany, ⁴Rheumatologist, Halle/ Salle, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, ⁶German Rheumatism Research Center (DRFZ), Berlin, Germany
Background/Purpose: The satisfaction of rheumatoid arthritis (RA) patients with their pharmacological therapy is a relevant patient reported outcome which influences treatment adherence and continuation. However,…
Abstract Number: 2817 • 2019 ACR/ARP Annual Meeting
Lysosomal Placement of the Energy Sensors AMPK and mTORC1 Controls Tissue Inflammation in Rheumatoid Arthritis
Zhenke Wen ¹, Ke Jin ¹, Yinyin Li ¹, Bowen Wu ¹, Jorg Goronzy ¹ and Cornelia Weyand¹, ¹Stanford University, Stanford, CA
Background/Purpose: CD4 T cells from patients with rheumatoid arthritis (RA) are metabolically reprogrammed, diverting glucose away from glycolysis towards the production of biosynthetic precursors. Several…
Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Frances humby ¹, Maya H. Buch ², Patrick Durez ³, Myles Lewis ¹, Michele Bombardieri ¹, Hasan Rizvi ⁴, Stephen Kelly ⁴, Liliane Fosatti ¹, Rebecca Hands ¹, Giovanni Giorli ¹, Arti Mahto ¹, Carlomaurizio Montecucco ⁵, Bernard Lauwerys ⁶, Vasco Romao ⁷, Arthur Pratt ⁸, Serena Bugatti ⁹, Nora Ng ¹⁰, Felice Rivellese ¹, Pauline Ho ¹¹, Mattia Bellan ¹², Mattia Congia ¹³, Patrick Verschueren ¹⁴, Pier Paolo Sainaghi ¹², Nagui Gendi ¹⁵, Bhaskar Dasgupta ¹⁶, Alberto Cauli ¹⁷, Piero Reynolds ¹⁸, Juan Cañete ¹⁹, Robert J. Moots ²⁰, Peter Taylor ²¹, Christopher Edwards ²², John Isaacs ⁸, Peter Sasieni ²³, João Eurico Fonseca ²⁴, Ernest Choy ²⁵ and Costantino Pitzalis²⁶, ¹Queen Mary University of London, London, United Kingdom, ²University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁶University of Louvain, Louvain, Belgium, ⁷University of Lisbon, Lisbon, Portugal, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹University of Pavia, Pavia, Italy, ¹⁰Guys and St Thomas NHS Trust, London, United Kingdom, ¹¹University of Manchester, Manchester, United Kingdom, ¹²University of Novara, Novara, Italy, ¹³University of Cagliari, Cagliari, Italy, ¹⁴University of Leuven, Leuven, Belgium, ¹⁵Basildon Hospital NHS Trust, Basildon, United Kingdom, ¹⁶Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ¹⁷Rheumatology Unit, University Clinic AOU and University of Cagliari, Cagliari, Italy, ¹⁸Homerton University NHS Trust, London, United Kingdom, ¹⁹Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ²⁰Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ²¹University of Oxford, Oxford, United Kingdom, ²²University of Southampton, Southampton, United Kingdom, ²³Kings College London, London, United Kingdom, ²⁴Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ²⁵Cardiff University School of Medicine, Cardiff, United Kingdom, ²⁶Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
Abstract Number: 498 • 2018 ACR/ARHP Annual Meeting
Trends in the Incidence of Cardiovascular Diseases in Patients with Rheumatoid Arthritis in Spain: A National Observational Cohort Study of Hospital Discharges
Cristina Macia-Villa¹, Ramon Mazzucchelli², E Perez-Fernandez², Javier Quirós², J.L Morell-Hita³, Natalia Crespí⁴, M Peña², Carmen Barbadillo⁵, Maria Espinosa⁶, Hilda Godoy⁵, Manuel Fernández⁷, María Galindo⁸, Alberto Garcia-Vadillo⁹, O Guzon-Illescas², Angela Herranz¹⁰, Cristina Martinez-Prada¹¹, C Morado-Quiñoa¹¹ and Virginia Villaverde García¹², ¹Hospital Universitario Severo Ochoa, Madrid, Spain, ²H.U.Fundación Alcorcón, Madrid, Spain, ³H.U.Ramón y Cajal, Madrid, Spain, ⁴C.S. La Rivota, Madrid, Spain, ⁵H.U. Puerta de Hierro, Madrid, Spain, ⁶Rheumatology, H.U. Puerta de Hierro, Madrid, Spain, ⁷Hospital Universitario de Guadalajara. Spain, Guadalajara, Spain, ⁸Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰H.U. del Henares, Madrid, Spain, ¹¹H.U. Clínico San Carlos, Madrid, Spain, ¹²Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain
Background/Purpose: Cardiovascular diseases (CVDs) are a worldwide health problem, with an increased risk in Rheumatoid Arthritis (RA) due to its inflammatory context, comorbidities and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.